NCI-H226

NCI-H226 is a cell line derived from human pleural effusion of a patient with squamous cell carcinoma of the lung. This cell line is commonly used in cancer research to study the biology of lung cancer and to test potential therapeutic agents.

History

The NCI-H226 cell line was established in 1982 by A.F. Gazdar, J.D. Minna, and colleagues at the National Cancer Institute (NCI) and the University of Texas Southwestern Medical Center. The cell line was derived from the pleural effusion of a 58-year-old Caucasian male with squamous cell carcinoma of the lung.

Characteristics

NCI-H226 cells are epithelial in morphology and grow in a monolayer. They have a high colony-forming efficiency in soft agar, indicating a high level of malignancy. The cells express epidermal growth factor receptor (EGFR), but not ALK or ROS1 rearrangements, which are common in non-small cell lung cancer.

Applications

NCI-H226 cells are used in a variety of research applications. They are particularly useful for studying the biology of squamous cell lung cancer, including the role of EGFR and other signaling pathways in the disease. The cells are also used to test potential therapeutic agents, including chemotherapy drugs and targeted therapies.

See also

• Cell line
• Cancer research
• Squamous cell carcinoma
• Lung cancer